Yttrium-90 radioembolization of hepatocellular carcinoma and metastatic disease to the liver

Robert J. Lewandowski; Riad Salem

doi:10.1055/s-2006-939842

Yttrium-90 radioembolization of hepatocellular carcinoma and metastatic disease to the liver

Robert J. Lewandowski, Riad Salem^*

^*Corresponding author for this work

Radiology

Research output: Contribution to journal › Review article › peer-review

77 Scopus citations

Abstract

Yttrium-90 (⁹⁰Y) radioembolization is a catheter-based therapy that delivers internal radiation to hepatic tumors in the form of microspheres. ⁹⁰Y can be delivered to the hepatic tumor as either a constituent of a glass microsphere, TheraSphere®, or as a biocompatible resin-based microsphere, SIR-Spheres®. Once embedded within the tumor microcirculation, these microspheres emit β-radiation at therapeutic levels. While the technical aspects of radioembolization are quite complex, the collective clinical experience presented in the literature supports the use of ⁹⁰Y radioembolization for unresectable hepatic malignancies.

Original language	English (US)
Pages (from-to)	64-72
Number of pages	9
Journal	Seminars in Interventional Radiology
Volume	23
Issue number	1
DOIs	https://doi.org/10.1055/s-2006-939842
State	Published - Mar 2006

Keywords

Hepatocellular carcinoma
Liver cancer
Liver tumor
Metastatic disease to the liver
Radioembolization
SIR-Sphere®
TheraSphere®
Yttrium-90

ASJC Scopus subject areas

Radiology Nuclear Medicine and imaging
Cardiology and Cardiovascular Medicine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1055/s-2006-939842

Cite this

@article{4dcc8d20a8df4efa909614eec14edb2d,

title = "Yttrium-90 radioembolization of hepatocellular carcinoma and metastatic disease to the liver",

abstract = "Yttrium-90 (90Y) radioembolization is a catheter-based therapy that delivers internal radiation to hepatic tumors in the form of microspheres. 90Y can be delivered to the hepatic tumor as either a constituent of a glass microsphere, TheraSphere{\textregistered}, or as a biocompatible resin-based microsphere, SIR-Spheres{\textregistered}. Once embedded within the tumor microcirculation, these microspheres emit β-radiation at therapeutic levels. While the technical aspects of radioembolization are quite complex, the collective clinical experience presented in the literature supports the use of 90Y radioembolization for unresectable hepatic malignancies.",

keywords = "Hepatocellular carcinoma, Liver cancer, Liver tumor, Metastatic disease to the liver, Radioembolization, SIR-Sphere{\textregistered}, TheraSphere{\textregistered}, Yttrium-90",

author = "Lewandowski, {Robert J.} and Riad Salem",

year = "2006",

month = mar,

doi = "10.1055/s-2006-939842",

language = "English (US)",

volume = "23",

pages = "64--72",

journal = "Seminars in Interventional Radiology",

issn = "0739-9529",

publisher = "Thieme Medical Publishers, Inc.",

number = "1",

}

TY - JOUR

T1 - Yttrium-90 radioembolization of hepatocellular carcinoma and metastatic disease to the liver

AU - Lewandowski, Robert J.

AU - Salem, Riad

PY - 2006/3

Y1 - 2006/3

N2 - Yttrium-90 (90Y) radioembolization is a catheter-based therapy that delivers internal radiation to hepatic tumors in the form of microspheres. 90Y can be delivered to the hepatic tumor as either a constituent of a glass microsphere, TheraSphere®, or as a biocompatible resin-based microsphere, SIR-Spheres®. Once embedded within the tumor microcirculation, these microspheres emit β-radiation at therapeutic levels. While the technical aspects of radioembolization are quite complex, the collective clinical experience presented in the literature supports the use of 90Y radioembolization for unresectable hepatic malignancies.

AB - Yttrium-90 (90Y) radioembolization is a catheter-based therapy that delivers internal radiation to hepatic tumors in the form of microspheres. 90Y can be delivered to the hepatic tumor as either a constituent of a glass microsphere, TheraSphere®, or as a biocompatible resin-based microsphere, SIR-Spheres®. Once embedded within the tumor microcirculation, these microspheres emit β-radiation at therapeutic levels. While the technical aspects of radioembolization are quite complex, the collective clinical experience presented in the literature supports the use of 90Y radioembolization for unresectable hepatic malignancies.

KW - Hepatocellular carcinoma

KW - Liver cancer

KW - Liver tumor

KW - Metastatic disease to the liver

KW - Radioembolization

KW - SIR-Sphere®

KW - TheraSphere®

KW - Yttrium-90

UR - http://www.scopus.com/inward/record.url?scp=33646117023&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646117023&partnerID=8YFLogxK

U2 - 10.1055/s-2006-939842

DO - 10.1055/s-2006-939842

M3 - Review article

C2 - 21326721

AN - SCOPUS:33646117023

SN - 0739-9529

VL - 23

SP - 64

EP - 72

JO - Seminars in Interventional Radiology

JF - Seminars in Interventional Radiology

IS - 1

ER -

Yttrium-90 radioembolization of hepatocellular carcinoma and metastatic disease to the liver

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this